Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Net Income towards Common Stockholders: 2013-2025

Historic Net Income towards Common Stockholders for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $9.0 million.

  • Coherus Oncology's Net Income towards Common Stockholders fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • Per Coherus Oncology's latest filing, its Net Income towards Common Stockholders stood at $9.0 million for Q3 2025, which was down 97.38% from $342.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Net Income towards Common Stockholders ranged from a high of $342.6 million in Q2 2025 and a low of -$172.9 million during Q1 2021.
  • For the 3-year period, Coherus Oncology's Net Income towards Common Stockholders averaged around $50.2 million, with its median value being $9.0 million (2025).
  • Per our database at Business Quant, Coherus Oncology's Net Income towards Common Stockholders crashed by 586.19% in 2021 and then surged by 717.15% in 2025.
  • Over the past 5 years, Coherus Oncology's Net Income towards Common Stockholders (Quarterly) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then slumped by 35.30% to -$79.7 million in 2023, then spiked by 348.34% to $197.8 million in 2024, then slumped by 75.61% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q3 2025, $342.6 million for Q2 2025, and -$9.2 million during Q1 2025.